Alkermes/$ALKS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Alkermes
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
Ticker
$ALKS
Sector
Primary listing
Employees
1,800
Headquarters
Dublin, Ireland
Website
Alkermes Metrics
BasicAdvanced
$4.6B
13.41
$2.08
0.40
-
Price and volume
Market cap
$4.6B
Beta
0.4
52-week high
$36.45
52-week low
$25.17
Average daily volume
1.8M
Financial strength
Current ratio
3.232
Quick ratio
2.712
Long term debt to equity
4.076
Total debt to equity
4.474
Interest coverage (TTM)
35.14%
Profitability
EBITDA (TTM)
403.272
Gross margin (TTM)
85.13%
Net profit margin (TTM)
23.15%
Operating margin (TTM)
24.86%
Effective tax rate (TTM)
15.19%
Revenue per employee (TTM)
$840,000
Management effectiveness
Return on assets (TTM)
10.49%
Return on equity (TTM)
23.94%
Valuation
Price to earnings (TTM)
13.412
Price to revenue (TTM)
3.025
Price to book
2.83
Price to tangible book (TTM)
2.99
Price to free cash flow (TTM)
9.491
Free cash flow yield (TTM)
10.54%
Free cash flow per share (TTM)
2.936
Growth
Revenue change (TTM)
-0.17%
Earnings per share change (TTM)
21.99%
3-year revenue growth (CAGR)
8.66%
10-year revenue growth (CAGR)
8.80%
3-year earnings per share growth (CAGR)
53.04%
10-year earnings per share growth (CAGR)
13.40%
What the Analysts think about Alkermes
Analyst ratings (Buy, Hold, Sell) for Alkermes stock.
Bulls say / Bears say
Alkermes Q2 revenue came in at $390.7 million, exceeding analyst expectations, and diluted EPS of $0.52 outpaced estimates by $0.16, lifting shares 5% before the market opened (Reuters)
Net sales of proprietary products rose 14% year-over-year to $307.2 million, driven by gains in Lybalvi (+18%), Aristada (+18%) and Vivitrol (+9%) (Reuters)
Wall Street remains upbeat, with 12 buy ratings and zero sells, supporting a median 12-month price target of $42—around 38% above current levels (Reuters)
Q2 revenue was partly boosted by favorable Medicaid gross-to-net adjustments, a one-time benefit that may not continue in future periods (Reuters)
The stock’s forward P/E ratio has dropped to 15x from 18x three months ago, indicating a valuation pullback as investors grow more cautious (Reuters)
The company chose to maintain its 2025 guidance instead of increasing it, suggesting limited near-term confidence in faster growth (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 5 Sept 2025.
Alkermes Financial Performance
Revenues and expenses
Alkermes Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Alkermes stock?
Alkermes (ALKS) has a market cap of $4.6B as of September 18, 2025.
What is the P/E ratio for Alkermes stock?
The price to earnings (P/E) ratio for Alkermes (ALKS) stock is 13.41 as of September 18, 2025.
Does Alkermes stock pay dividends?
No, Alkermes (ALKS) stock does not pay dividends to its shareholders as of September 18, 2025.
When is the next Alkermes dividend payment date?
Alkermes (ALKS) stock does not pay dividends to its shareholders.
What is the beta indicator for Alkermes?
Alkermes (ALKS) has a beta rating of 0.4. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.